




© AGO e. V.
in der DGGG e. V.
sowie
in der DKG e. V.

Guidelines Breast
Version 2020.1

FORSCHEN
LEHREN
HEILEN

Diagnosis and Treatment of Patients with early and advanced Breast Cancer

Adjuvant Cytotoxic and Targeted Therapy



© AGO e. V.
in der DGGG e.V.
sowie
in der DKG e.V.

Guidelines Breast
Version 2020.1

www.ago-online.de

FORSCHEN
LEHREN
HEILEN

Adjuvant Cytotoxic and Targeted Therapy

- **Versionen 2002 – 2019:**
Dall / Harbeck / Jackisch / Janni / Loibl / Lux/
von Minckwitz / Möbus / Müller / Nitz / Schmidt / Schneeweiss / Simon /
Schütz / Solomayer / Stickeler / Thill / Thomssen / Untch
- **Version 2020:**
Fehm / Stickeler


Systematic review of published evidence

PUBMED 1999-2019

ASCO 1999-2019

SABCS 1999-2019

ECCO/ESMO 1999-2019

|  | <h1>Subtype-specific Strategies for Systemic Treatment</h1> | |
|---|--|----|
| <p>© AGO e. V. in der DGGG e.V. sowie in der DKG e.V.</p> <p>Guidelines Breast Version 2020.1</p> | <u>AGO</u> | |
| <p>If chemotherapy is indicated, systemic treatment before surgery (neoadjuvant) should be preferred</p> | | |
| <p>HR+/HER2- and „low-risk“</p> | <ul style="list-style-type: none"> Endocrine therapy without chemotherapy | ++ |
| <p>HR+/HER2- and „high-risk“</p> | <ul style="list-style-type: none"> Conventionally dosed AT- based chemotherapy (q3w) | + |
| | <ul style="list-style-type: none"> Dose dense chemotherapy (including weekly schedule) | ++ |
| | <ul style="list-style-type: none"> Followed by endocrine therapy | ++ |
| <p>HER2+</p> | <ul style="list-style-type: none"> Trastuzumab (plus Pertuzumab in N+ or NACT) | ++ |
| | <ul style="list-style-type: none"> Sequential A/T-based regimen with concurrent T + anti-HER2 therapy | ++ |
| | <ul style="list-style-type: none"> Anthracycline-free, platinum-containing regimen | + |
| | <ul style="list-style-type: none"> Anthracycline-free, taxane-containing regimen | + |
| <p>Triple-negativ (TNBC)</p> | <ul style="list-style-type: none"> Conventionally dosed AT-based chemotherapy | + |
| | <ul style="list-style-type: none"> Dose dense chemotherapy (AT - based including weekly schedule) | ++ |
| | <ul style="list-style-type: none"> Neoadjuvant platinum-containing chemotherapy | + |

www.ago-online.de

FORSCHEN
LEHREN
HEILEN


Systematic review of published evidence

PUBMED 1999-2019

ASCO 1999-2019

SABCS 1999-2019

ECCO/ESMO 1999-2019



© AGO e. V.
in der DGGG e.V.
sowie
in der DKG e.V.

Guidelines Breast
Version 2020.1

www.ago-online.de

FORSCHEN
LEHREN
HEILEN


Adjuvant Chemotherapy: TNBC

■ **Indication for chemotherapy in node-negative disease**

- > 10 mm
- > 5–10 mm
- ≤ 5 mm

| | Oxford LoE | GR | AGO |
|--|---------------|----|-----|
| | 2b | B | ++ |
| | 2b | B | + |
| | 2b | B | - |

1. Gamucci T, Vaccaro A, Ciancola F et. al. Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis. J Cancer Res Clin Oncol. 2013;139(5):853-60. doi: 10.1007/s00432-013-1388-2. Epub 2013 Feb 15.
2. Kolben T, Harbeck N, Wuerstlein R et al. Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry. Breast. 2015;24(1):24-31. doi: 10.1016/j.breast.2014.10.007. Epub 2014 Nov 8.
3. Nonneville A, Goncalves C, Zemmour M et al. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study . European J Cancer. 2017; (84):34-43.



© AGO e. V.
in der DGGG e.V.
sowie
in der DKG e.V.

Guidelines Breast
Version 2020.1

www.ago-online.de

FORSCHEN
LEHREN
HEILEN

Adjuvant Chemotherapy without Trastuzumab: Overview

| | Oxford | | |
|--|-----------|----------|------------|
| | LoE | GR | AGO |
| ■ Dose-dense anthracycline / taxane based (incl. weekly) chemotherapy | 1a | A | ++ |
| ■ Conventional anthracycline-/taxane based (q3w) | 1a | A | + |
| ■ „Tailored“ anthracycline-/taxane based | 1b | B | +/- |
| ■ If anthracyclines cannot be given | | | |
| ■ Docetaxel plus cyclophosphamide | 1b | B | + |
| ■ Paclitaxel mono weekly | 1b | B | +/- |
| ■ CMF | 1a | A | +/- |
| ■ Low-dose maintenance chemo | 1b | B | - |

Statement: Dosis-dicht Anthrazyklin-/ Taxan-basiert (inkl. weekly) LoE 1a A AGO ++

1. Moylan EJ, Connell LC, O'Reilly S et al. Are dose-dense and triplet chemotherapy regimens optimal adjuvant therapy in the majority of women with node-positive early breast cancer? J Clin Oncol. 2014;32(6):605-6.
2. Lemos Duarte I, da Silveira Nogueira Lima JP, Passos Lima CS et al. Dose-dense chemotherapy versus conventional chemotherapy for early breast cancer: a systematic review with meta-analysis. Breast. 2012;21(3):343-9.
3. Möbus V, Jackisch C, Lück HJ et al. Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial. Ann Oncol. 2018 Jan 1;29(1):178-185.
4. Gray R, Bradley R, Braybrooke J et al. Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: An EBCTCG meta-analysis of 21,000 women in 16 randomised trials. SABCS 2017, abstr. GS1-01
5. Budd GT, Barlow WE, Moore HC et al. SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer. J Clin Oncol. 2015 Jan 1;33(1):58-64.
6. Zhou W, Chen S, Xu F, Zeng X. Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized

controlled trials. World J Surg Oncol. 2018 Jul 14;16(1):144.

7. Goldvaser H, Majeed H, Ribnikar D et al. Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis. Breast Cancer Res Treat. 2018 Jun;169(3):413-425.
8. Matikas A, Foukakis T, Moebus V et al. Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients. Ann Oncol. 2019 Jan 1;30(1):109-114.

Statement: Konventionell Anthrazyklin-/ Taxan-basiert (q3w) LoE 1a A AGO +

1. Budd GT, Barlow WE, Moore HC et al. SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer. J Clin Oncol. 2015 Jan 1;33(1):58-64.
2. EBCTCG, Peto R, Davies C, Godwin J et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379(9814):432-44
3. Denduluri N, Chavez-MacGregor M, Telli ML et al. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2018 Aug 10;36(23):2433-2443.

Statement: „Tailored“ Anthrazyklin-/ Taxan-basiert LoE 1b B AGO +/-

1. Matikas A, Foukakis T, Moebus V, et al. Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients. Ann Oncol. 2019 Jan 1;30(1):109-114.

Statement: If anthracyclines cannot be given - Docetaxel plus cyclophosphamide

1. Jones S, Holmes FA, O'Shaughnessy J et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. Clin Oncol. 2009;27(8):1177-83.

Statement: If anthracyclines cannot be given - Paclitaxel mono weekly


1. Amoroso V, Pedersini R, Sharratt P et al. Should adjuvant weekly Paclitaxel be considered less efficacious than anthracyclines plus cyclophosphamide for lower-risk patients with early-stage breast cancer? J Clin Oncol. 2015 Jan 20;33(3):290.
2. Shulman LN, Berry DA, Cirincione CT et al. Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014 Aug 1;32(22):2311-7.
3. Sparano JA, Wang M, Martino S et al. Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer. N Engl J Med. 2008 Apr 17;358(16):1663-71

Statement: If anthracyclines cannot be given - CMF

1. Perrone F, Nuzzo F, Di Rella F et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Ann Oncol. 2015;26(4):675-82.

Statement: Low dose maintenance Chemotherapy

1. Colleoni, Viale G, Goldhirsch A. Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group trial 22-00. J Clin Oncol 2016;34:3400-8



© AGO e. V.
in der DGGG e. V.
sowie
in der DKG e. V.

Guidelines Breast
Version 2020.1

www.ago-online.de

FORSCHEN
LEHREN
HEILEN

Gray R et al., Lancet 2019

Early Breast Cancer Trialists' Cooperative Group (EBCTCG)

Increasing the dose-density of adjuvant chemotherapy: an EBCTCG meta-analysis

Same chemotherapy drugs and doses (**n = 10,004**)

Recurrence-free survival: 10-y Gain 4.3% (95%-C.I. 2.2 – 6.5)
(RR = 0.83; 95%-C.I. 0.76 – 0.91; p<0.0001)

Overall survival: 10-y Gain 2.8% (95%-C.I. 0.8 – 4.8)
(RR = 0.86; 95%-C.I. 0.77 – 0.96; p=0.0054)

ER negative: **10-y Gain 4.7%** (95%-C.I. 2.3 – 7.1)
ER positive: **10-y Gain 3.1%** (95%-C.I. 1.5 – 4.7)

1. Gray R, Bradley R, Braybrooke J et al. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.

[Lancet](#). 2019;393(10179):1440-1452. doi: 10.1016/S0140-6736(18)33137-4. Epub 2019 Feb 8

© AGO e. V.
in der DGGG e.V.
sowie
in der DKG e.V.

Guidelines Breast
Version 2020.1

Recommended Dose-dense and / or Dose-escalated, Sequential Adjuvant Chemotherapy *

Dose-dense regimen

- A₆₀ X4 → Pac₁₇₅ x4 → C₆₀₀ x4 q2w
- A₆₀C q2w x4 → Pac₁₇₅ q2w x 4
- E₉₀C q2w x4 → Pac₁₇₅ q2w x 4
- E₉₀C q2w x4 → Pac₈₀ q1w x 12

Dose-dense and dose-escalated regimen (N ≥ 4+)

- E₁₅₀ → Pac₂₂₅ → C₂₅₀₀ q2w

| | Oxford | | |
|----|--------|----|-----|
| | LoE | GR | AGO |
| 1b | A | ++ | |
| 1b | B | ++ | |
| 1b | A | ++ | |
| 1b | B | ++ | |
| 1b | A | ++ | |

* G-CSF obligatory

www.ago-online.de

FORSCHEN
LEHREN
HEILEN

Statement: Dose-dense regimen

A60x4 - Pac175x4 - C600x4 q2w / ACPac / AC-Pac q2w

1. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-9.

Statement: Dose-dense regimen

AC /EC q2w x 4 Pac q2w x 4

1. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-9.
2. Burnell M, Levine MN, Chapman JA et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and

cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol 28:77-82, 2010.

3. Del Mastro L, De Placido S, Bruzzi P et al. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. Lancet. 2015;385(9980):1863-72
4. Budd GT, Barlow WE, Moore HC et al. SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol. 2015 Jan 1;33(1):58-64.
5. Gray R, Bradley R, Braybrooke J et al. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet. 2019 Apr 6;393(10179):1440-1452. doi: 10.1016/S0140-6736(18)33137-4. Epub 2019 Feb 8

Statement: Dose-dense regimen

EC q2w / Pac q1w

EC q3w / Pac q1w

1. Sparano JA, Zhao, F Martino S et al. Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. J Clin Oncol 2015;33:2353-60.
2. Jones RL, Walsh G, Ashley S et al. A randomized pilot phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. Br J Cancer 2009;100:305-10.
3. Budd GT, Barlow WE, Moore HC et al. SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol. 2015 Jan 1;33(1):58-64.

EBCTCG Metaanalyse

1. Gray R, Bradley R, Braybrooke J et al. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet. 2019 Apr 6;393(10179):1440-1452. doi: 10.1016/S0140-6736(18)33137-4. Epub 2019 Feb 8


Statement: Dose-dense and dose-escalated regimen ($N \geq 4+$)

E-Pac-C q2w

1. Möbus V, Jackisch C, Lück HJ et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol. 2010 Jun 10;28(17):2874-80.
2. Möbus V, Jackisch C, Lück HJ et al. AGO Breast Study Group (AGO-B) Ten-year Results of Intense Dose-dense chemotherapy show superior survival compared to a conventional schedule in High-risk Primary Breast Cancer: Final results of AGO Phase III iddEPC trial. Ann Oncol. 2017 Oct 24. doi: 10.1093/annonc/mdx690. [Epub ahead of print]

Negative Trial

1. Swain SM, Tang G, Geyer CE Jr et al. Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. J Clin Oncol. 2013 Sep 10;31(26):3197-204.
2. Möbus V, von Minckwitz G, Jackisch C et al. German Breast Group (GBG), the AGO Breast Study Group (AGO-B) and NOGGO Study Groups. German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients. Ann Oncol. 2017 Aug 1;28(8):1803-1810.

| Recommended Conventional Regimens for Adjuvant Chemotherapy | | | |
|---|--|--|-----------------------|
|  <p>© AGO e. V. in der DGGG e. V. sowie in der DKG e. V.</p> <p>Guidelines Breast Version 2020.1</p> <p>www.ago-online.de</p> <p>FORSCHEN LEHREN HEILEN</p> | * Extrapolation from doxorubicin trials | | |
| | Anthracycline- / taxane-based regimen | | |
| | *EC q3w x 4 → P _{ac} q1w x 12 | | Oxford LoE GR AGO |
| | AC q3w x 4 → Pac q1w y 12 | | 2b B ++ |
| | AC → D | A ₆₀ C q3w x 4 → D ₁₀₀ x 4 | 1b A ++ |
| | *EC → D | E ₉₀ C q3w x 4 → D ₁₀₀ x 4 | 1b A + |
| | DAC | D ₇₅ A ₅₀ C q3w x 6 | 1b B + |
| | Anthracycline-free regimen | | |
| | DC corresponds to EC → D | D ₇₅ C ₆₀₀ x 6 | 1b B + |
| | DC >> 4 x AC | D ₇₅ C ₆₀₀ x 6 | 1b B + |
| | Pac mono | P ₈₀ q1w x 12 | 1b B +/- |
| | CMF | | 1a A +/- |
| | Taxane-free regimen (if pN0) | | |
| | FE ₁₀₀ C x 6 | F ₅₀₀ E ₁₀₀ C ₅₀₀ x 6 | 2b ^(a) B + |

Statement: Anthracycline/ taxane based regimen

*EC → Pw E90C q3w x 4 → P80 qw1 x 12

1. Sparano JA, Zhao, F Martino S et al. Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. J Clin Oncol 2015;33:2353-60.

Statement: Anthracycline/ taxane based regimen

AC → Pw A60Cq3w x 4 → P80qw1 x 12

1. Mamounas EP, Bryant J, Lembersky B et al. Paclitaxel After Doxorubicin Plus Cyclophosphamide As Adjuvant Chemotherapy for Node-Positive Breast Cancer: Results From NSABP B-28 J Clin Oncol 2005;23:3686-3696.
2. Sparano JA, Zhao, F Martino S et al. Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. J Clin Oncol 2015;33:2353-60

Statement: Anthracycline/ taxane based regimen

AC → D A60C q3w x 4 → D100 qw3 x 4

EC → D E90C q3w x 4 → D100 qw3 x 4

1. Denduluri N, Chavez-MacGregor M, Telli ML et al. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2018 Aug 10;36(23):2433-2443.

Statement: Anthracycline/ taxane based regimen

DAC D75A50C q3w x 6

1. Swain SM, Tang G, Geyer CE Jr et al. Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. J Clin Oncol. 2013;31(26):3197-204.
2. Blum JL, Flynn PJ, Yothers G et al. Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol. 2017;35(23):2647-2655.

Statement: Anthracycline-free regimen

DC → D75 C600 x4 corresponds to EC → D

1. Harbeck N, Gluz O, Wuerstlein R et al. No age-related outcome disparities according to 21-gene recurrence score groups in early breast cancer patients treated by adjuvant chemotherapy in the prospective WSG PlanB trial. SABCS 2017, abstr.P1-06-06

Statement: Anthracycline-free regimen

DC >> 4 x AC

1. Jones S, Holmes FA, O'Shaughnessy J et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Oncol. 2009;27(8):1177-83.

Statement: Anthracycline-free regimen

Pac mono 80 mg q1w x 4-6

1. Shulman LN, Burstein HJ, Winer EP et al. Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014;32:2311-7.

Statement: Anthracycline-free regimen

CMF 600/40/600 mg q3w x 6

1. Perrone F, Nuzzo F, Di Rella F et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Ann Oncol. 2014;26:675-82

Statement: Taxan-freie Schemata (bei pN0)

FE100C x 6 q3w

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005 May 14-20;365(9472):1687-717.
2. Thomssen C, Vetter M, Kantelhardt EJ et al. on behalf of the NNBC-3 Study Group Adjuvant therapy with FEC and docetaxel in high risk node-negative breast cancer patients identified by tumor-biological (uPA/PAI-1) or clinico-pathological risk assessment. A joint trial of AGO-Breast Study Group, German Breast Group and EORTC Pathology and Biomarker Group (NNBC 3-Europe). Submitted

| Adjuvant Chemotherapy Other Drugs | | | |
|---|-----------------|----|-----|
| | Oxford | | |
| | LoE | GR | AGO |
| <ul style="list-style-type: none"> Capecitabine-containing regimen in TNBC <ul style="list-style-type: none"> in general postneoadjuvant in non-pCR patients* | 1a | B | +/- |
| | 1a ^a | A | - |
| | 1a ^a | A | + |
| <ul style="list-style-type: none"> Platinum-containing regimen in TNBC | 5 | D | + |
| <ul style="list-style-type: none"> 5- fluorouracile added to EC/AC | 1b | A | -- |

*no platinum pretreatment

Statement: Capecitabine containing regimen in TNBC

1. O'Shaughnessy J, Koeppen H, Xiao Y et al. Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine. Clin Cancer Res. 2015;21:4305-11
2. Jiang Y, Yin W, Zhou L et al. First efficacy results of capecitabine with anthracycline-and taxane-based adjuvant therapy in high-risk early breast cancer: a meta-analysis. PLoS ONE 2012;7(3): e32474.
3. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R et al. Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial. JAMA Oncol. 2017;3(6):793-800.
4. Martín M, Barrios CH, Torrecillas L et al. Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer. San Antonio Breast Cancer Symposium 2018, abstr. GS2-04.
5. Van Mackelenbergh M Seiter F, Möbus V et al. Effects of capecitabine as part of neo-/adjuvant chemotherapy. A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients. SABCS 2019, abstr. GS1-07

Statement: Capecitabine containing regimen in TNBC in general:

1. Martín M, Barrios CH, Torrecillas L et al. Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer. San Antonio Breast Cancer Symposium 2018, abstr. GS2-04.

Statement: Capecitabine containing regimen in TNBC as postneoadjuvant therapy if non-pCR:

1. Masuda N, Lee SJ, Ohtani S et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med. 2017 Jun 1;376(22):2147-59.

Statement: 5- Fluorouracile added to EC/AC=>Pac


1. Del Mastro L, De Placido S, Bruzzi P et al. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. Lancet. 2015;385(9980):1863-72.

Statement: Platinum containing regimen in TNBC

1. Joensuu H, Gligorov J. Adjuvant treatments for triple-negative breast cancers. Ann Oncol. 2012;23 Suppl 6:vi40-5.
2. Alba E, Chacon JI, Lluch A et al. A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Res Treat 2012: 136; 487–493.
3. Von Minckwitz G, Schneeweiss A, Loibl S et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014: 15; 747-56.
4. Ando M, Yamauchi H, Aogi K et al. Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression. Breast Cancer Res Treat 2014: 145; 401-09.
5. Petrelli F, Coinu A, Borgonova K et al. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a

systematic review and meta-analysis. Breast Cancer Res Treat 2014; 144; 223-32.

6. Sikov WM, Berry DA, Perou CM et al. Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). J Clin Oncol 2015; 33; 13-21.
7. Loibl S, O'Shaughnessy J, Untch M et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018 Apr;19(4):497-509.
8. Gluz O Nitz U, Liedtke C et al. Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results. J Natl Cancer Inst. 2018 Jun 1;110(6):628-637.



© AGO e. V.
in der DGGG e. V.
sowie
in der DKG e. V.

Guidelines Breast
Version 2020.1

www.ago-online.de

FORSCHEN
LEHREN
HEILEN

Van Mackelenbergh M et al., SABCS 2019, abstr. GS1-07

Effects of capecitabine as part of neo-/adjuvant chemotherapy

Meta-analysis of individual patient data from 12 randomized trials (n=15,457)

HR for DFS overall 0.952 (95%-C.I. 0.895-1.012, p=0.115)
X add. 0.888 (95%-C.I. 0.817-0.965, p=0.005)
X instead 1.035 (95%-C.I. 0.945-1.134, p=0.455)

HR for OS overall 0.892 (95%-C.I. 0.824-0.965, p=0.005)
X add. 0.837 (95%-C.I. 0.751-0.933, p=0.001)
X instead 0.957 (95%-C.I. 0.853-1.073, p=0.450)


Significance only for TNBC overall DFS 0.886 (95%-C.I. 0.789-0.994, p=0.040)
OS 0.828 (95%-C.I. 0.720-0.952, p=0.008)
X add.: DFS 0.818 (95%-C.I. 0.713-0.938, p=0.004)
OS 0.778 (95%-C.I. 0.657-0.921, p=0.004)


1. Van Mackelenbergh M Seiter F, Möbus V et al. Effects of capecitabine as part of neo-/adjuvant chemotherapy. A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients. SABCS 2019, abstr. GS1-07

| | Oxford | | |
|--|-----------------|----|-----|
| | LoE | GR | AGO |
| Trastuzumab + Pertuzumab | | | |
| ▪ pN+ | 1b ^a | B | + |
| ▪ pN- | 1b ^a | B | +/- |
| Trastuzumab in node-negative disease (if chemotherapy is indicated) | | | |
| ▪ > 10 mm | 1a | A | ++ |
| ▪ > 5–10 mm | 2b | B | + |
| ▪ ≤ 5 mm | 2b | B | +/- |

Statement Trastuzumab + Pertuzumab (pN+/-)

1. von Minckwitz G, Procter M, de Azambuja E et al; APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017;377(2):122-131.
2. Piccart M , Procter M, Fumagalli D et al. Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer. SABCS 2019; abstr. GS 01-04






© AGO e. V.
in der DGGG e.V.
sowie
in der DKG e.V.

Guidelines Breast
Version 2020.1

www.ago-online.de



Aphinity-Trial - Update

Clinical benefit of the dual blockade with trastuzumab / pertuzumab


| HR (95%-CI) for IDFS | | | 6-yr-IDFS rate | | |
|----------------------|---------------------------|--------------------|----------------|-------------|-------------------------|
| Group | Primary analysis (2017) * | Update (2019)** | Pertuzumab arm | Placebo arm | Absolute benefit 95%-CI |
| ITT | 0,81 (0,66-1,00) | 0,76 (0,64 -0,91) | 90,6% | 87,8% | 2,8% (1,0-4,6) |
| N+ | 0,77 (0,62-0,96) | 0,72 (0,59-0,87) | 87,9% | 83,4% | 4,5% (1,9-7,1) |
| N0 | 1,13 (0,58-1,86) | 1,02 (0,69-1,53) | 95,0% | 94,9% | 0,1% (-2,0 -2,2) |
| HR pos | 0,86 (0,56-1,13) | 0,73 (0,59 – 0,92) | 91,2% | 88,2% | 3,0% (0,8-5,2) |
| HR neg | 0,76 (0,56-1,04) | 0,83 (0,63-1,10) | 89,5% | 87,0% | 2,5% (-0,7-5,6) |

* FU: 45,5 mths; ** FU: 74,1 mths


OS difference after 74.1 mths of median follow-up did not reach statistical significance

Mod. Nach Piccart M et al. SABCS 2019; abstr. GS1-04

Piccart M , Procter M, Fumagalli D et al. Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer. SABCS 2019; abstr. GS 01-04



ARBEITSGEMEINSCHAFT
GYNAKOLOGISCHE
ONKOLOGIE e.V.



12-2019-2022

© AGO e. V.
in der DGGG e.V.
sowie
in der DKG e.V.

Guidelines Breast
Version 2020.1

www.ago-online.de

FORSCHEN
LEHREN
HEILEN

Adjuvant treatment with trastuzumab

Start of treatment

- Simultaneously with taxanes
- Sequentially up to 3 months after chemotherapy
- s.c. = i.v.

| | Oxford | | |
|----|--------|----|-----|
| | LoE | GR | AGO |
| 1a | A | ++ | |
| 1b | B | + | |
| 1a | A | ++ | |

Duration

- For 1 year
- For 0.5 years
- For 2 years

| | | |
|----|---|----|
| 1a | A | ++ |
| 1a | A | + |
| 1b | A | - |

Statement: Start of treatment simultaneously with taxanes

1. Smith I, Procter M, Gelber RD et al.; HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369(9555):29-36.
2. Goldhirsch A, Gelber RD, Piccart-Gebhart, MJ et al.; Herceptin Adjuvant (HERA) Trial Study Team. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013;382(9897):1021-8.
3. Cameron D, Piccart-Gebhart MJ, Gelber RD, et al.; Herceptin Adjuvant (HERA) Trial Study Team. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389(10075):1195-1205.
4. Perez EA, Romond EH, Suman VJ et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32(33):3744-52.
5. Joensuu H, Bono P, Kataja V et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol. 2009;27(34):5685-92.
6. Yin W, Jiang Y, Shen Z et al. Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis

of published randomized controlled trials. PLoS One. 2011;6(6):e21030.

7. Perez EA, Suman VJ, Davidson NE et al. Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer. J Clin Oncol 2011;29:4491-4497
8. Slamon D, Eiermann W, Robert N et al.; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273-83.

Statement s.c.

1. Gligorov J, Ataseven B, Verrill M et al.; SafeHer Study Group. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. Eur J Cancer. 2017;82:237-246.
2. Pivot X, Verma S, Fallowfield L et al.; PrefHer Study Group. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study. Eur J Cancer. 2017;86:82-90.
3. Jackisch C, Stroyakovskiy D, Pivot X et al. Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial. JAMA Oncol. 2019;5(5):e190339. doi: 10.1001/jamaoncol.2019.0339.

Statement: Duration

Duration Trastuzumab 1 year

Duration Trastuzumab 2 year

Duration Trastuzumab 0.5 years

1. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ et al.; Herceptin Adjuvant (HERA) Trial Study Team. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. *Lancet*. 2013;382(9897):1021-8.
2. Cameron D, Piccart-Gebhart MJ, Gelber RD, et al.; Herceptin Adjuvant (HERA) Trial Study Team. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. *Lancet*. 2017;389(10075):1195-1205.
3. Joensuu H, Fraser J, Wildiers H et al. Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial. *JAMA Oncol*. 2018;4(9):1199–1206.
4. Conte P, Frassoldati A, Bisagni G et al. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. *Ann Oncol*. 2018;29(12):2328-2333.
5. Pivot X, Romieu G, Debled Met al. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. *Lancet*. 2019;393(10191):2591-2598. doi: 10.1016/S0140-6736(19)30653-1.
6. Earl HM, Hiller L, Vallier AL et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. *Lancet*. 2019;393(10191):2599-2612. doi: 10.1016/S0140-6736(19)30650-6.

Metaanalyses analyzing optimal duration:

1. Chen L, Zhou W, Hu X et al. Short-duration versus 1-year adjuvant trastuzumab in early HER2 positive breast cancer: A meta-analysis of randomized controlled trials. *Cancer Treat Rev*. 2019;75:12-19. doi: 10.1016/j.ctrv.2019.02.003.
2. Inno A, Barni S, Ghidini A et al. One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis. *Breast Cancer Res Treat*. 2019;173(2):247-254. doi: 10.1007/s10549-018-5001-x.
3. Niraula S, Gyawali B. Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials. *Breast Cancer Res Treat*. 2019;173(1):103-109. doi: 10.1007/s10549-018-4967-8.

4. Goldvaser H, Korzets Y, Shepshelovich D et al. Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis. JNCI Cancer Spectr. 2019;3(2):pkz033. doi: 10.1093/jncics/pkz033.

| Adjuvant Treatment with Trastuzumab +/- Pertuzumab: Chemotherapy regimen | | | |
|--|--------|----|-----|
| | Oxford | | |
| | LoE | GR | AGO |
| Trastuzumab simultaneously with | | | |
| ▪ paclitaxel / docetaxel after AC / EC | 1a | A | ++ |
| ▪ P q1w 12 x in pT < 2 cm, pN0 | 2b | B | + |
| ▪ docetaxel and carboplatin | 1b | A | + |
| Trastuzumab + Pertuzumab simultaneously with | | | |
| ▪ paclitaxel q1w (or docetaxel q3w) after EC/AC | 1b | B | ++ |
| ▪ docetaxel+ carboplatin | 1b | B | + |
| ▪ taxanes dose-dense | 2b | B | +* |
| Radiotherapy concurrently with Trastuzumab | 2b | B | + |

© AGO e. V.
in der DGGG e.V.
sowie
in der DKG e.V.
Guidelines Breast
Version 2020.1

www.ago-online.de
FORSCHEN
LEHREN
HEILEN

Statement: with paclitaxel/docetaxel after AC/EC

1. Perez EA, Suman VJ, Davidson NE et al. Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer. J Clin Oncol 2011;29:4491-4497
2. Cameron D, Piccart-Gebhart MJ, Gelber RD, et al.; Herceptin Adjuvant (HERA) Trial Study Team. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389(10075):1195-1205.
3. Papakonstantinou A, Matikas A, Bengtsson NO et al. Efficacy and Safety of Tailored and Dose-Dense Adjuvant Chemotherapy and Trastuzumab for Resected HER2-Positive Breast Cancer: Results From the Phase 3 PANTHER Trial. Cancer 2019 doi: 10.1002/cncr.32653. [Epub ahead of print]

Statement: P q1w12 in pT < 2 cm pN0

1. Tolaney SM, Barry WT, Dang CT et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015;372(2):134-41.
2. Tolaney SM, Guo H, Pernas S et al. Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative,

Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Clin Oncol. 2019;37(22):1868-1875. doi: 10.1200/JCO.19.00066.

Statement: with docetaxel and carboplatin

1. Valero V, Forbes J, Pegram MD et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol. 2011;29(2):149-56.
2. Burstein HJ, Piccart-Gebhart MJ, Perez EA et al. Choosing the Best Trastuzumab-Based Adjuvant Chemotherapy Regimen: Should We Abandon Anthracyclines? Journal of Clinical Oncology 2012;18(30):2179-2182

Statement: Trastuzumab + Pertuzumab simultaneously with Paclitaxel q1w or Docetaxel q3w (after EC or AC)

1. von Minckwitz G, Procter M, de Azambuja E et al; APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017;377(2):122-131.

Statement: Trastuzumab + Pertuzumab simultaneously with Docetaxel and Carboplatin q3w

1. von Minckwitz G, Procter M, de Azambuja E et al; APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017;377(2):122-131.
2. Schneeweiss A, Chia S, Hickish T et al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer 89:27-35, 2017


Statement: Trastuzumab + Pertuzumab simultaneously with taxanes dose-dense

1. von Minckwitz G, Procter M, de Azambuja E et al; APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and

Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017;377(2):122-131.

Statement: radiotherapy concurrent with trastuzumab

1. M. Y. Halyard, T. M. Pisansky, L. J. Solin et al. Trastuzumab can be administered concurrent to adjuvant radiotherapy of the breast or thoracic wall. Adjuvant radiotherapy (RT) and trastuzumab in stage I-IIA breast cancer: Toxicity data from North Central Cancer Treatment Group Phase III trial N9831 J Clin Oncol. 2009;27(16):2638-44



© AGO e. V.
in der DGGG e.V.
sowie
in der DKG e.V.

Guidelines Breast
Version 2020.1

www.ago-online.de

FORSCHEN
LEHREN
HEILEN

Adjuvant Therapy With Other Targeted Agents

- **Lapatinib**
 - (delayed adjuvant treatment)
- **Lapatinib + Trastuzumab**
- **Neratinib*** (one year) after completing a year of adjuvant trastuzumab (if HR-positive)
- **Bevacizumab**

| Oxford | | |
|-----------------------|----------|-----------|
| LoE | GR | AGO |
| 1b^a | B | - |
| 1b | B | - |
| 1b^a | B | - |
| 1b | B | + |
| 1b | B | -- |

* In addition to standard endocrine treatment

Statement: Lapatinib

Delayed adjuvant treatment

1. Moreno-Aspitia A, Dueck AC, Ghanem-Cañete I et al. RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer. Breast Cancer Res Treat. 2013;138(2):427-35.
2. Goss PE, Smith IE, O'Shaughnessy J.; TEACH investigators. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(1):88-96.
3. Perez EA, Holmes E, De Azambuja E et al. Disease-free survival (DFS) in the lapatinib alone arm and expanded results of the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) in the adjuvant treatment of HER2-positive early breast cancer (EBC). Ann Oncol 2014;25(5):1-41

Statement: Lapatinib + Trastuzumab

1. Piccart-Gebhart M, Holmes E, Baselga J et al. Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. J Clin Oncol. 2016 1;34(10):1034-42.

Statement: Neratinib

1. Martin M, Holmes FA, Ejlertsen B et al.; ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(12):1688-1700

Statement: Bevacizumab

1. Cameron D, Brown J, Dent R et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol. 2013;14(10):933-42.
2. Slamon D et al.. BETH: A Randomized Phase III Study Evaluating Adjuvant Bevacizumab Added to Trastuzumab/Chemotherapy for Treatment of HER2+ Early Breast Cancer. SABCS 2013
3. Miller KD, O'Neill A, Gradishar W et al. Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol. 2018;36(25):2621-2629.

AGO
ARBEITSGEMEINSCHAFT
GYNAEKOLOGISCHE
ONKOLOGIE e.V.

MAMMA
KR

© AGO e. V.
in der DGGG e.V.
sowie
in der DKG e.V.

Guidelines Breast
Version 2020.1

www.ago-online.de

FORSCHEN
LEHREN
HEILEN

Postneoadjuvant Therapy

| | Oxford | | |
|--|--------|----|-----|
| | LoE | GR | AGO |
| <u>HR-positive (pCR and non-pCR)</u> | | | |
| ▪ Endocrine therapy according to menopausal status (see. ch. 10) | 1a | A | ++ |
| ▪ Capecitabine (in case of non-pCR) | 3b | C | +/- |
| <u>HER2-positive (in case of pCR)</u> | | | |
| ▪ Low-risk: Trastuzumab (to complete 12 months) | 2a | C | ++ |
| ▪ High-risk (N+): Trastuzumab + Pertuzumab (to complete 12 months) | 2b | C | + |
| <u>HER2-positive (in case of non-pCR)</u> | | | |
| ▪ T-DM1 | 1b | B | + |
| ▪ Neratinib after 1 year* Trastuzumab (HR-positive) | 3b | B | +/- |
| ▪ Trastuzumab + Pertuzumab (to complete 12 months) | 2b | C | +/- |
| <u>Triple negative (TNBC) (if non-pCR)</u> | | | |
| ▪ Capecitabine (up to 8 courses)** | 1b | B | + |
| * in combination with standard endocrine therapy | | | |
| ** without platin based previous therapy | | | |

Statement ER and/or PgR positiv (pCR und non-pCR) Endokrine Therapie nach Menopausenstatus (s. Kap. 10)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-717.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341-1352.

Statement HER2 positiv (bei pCR): Low risk: Trastuzumab (bis 12 Mon. komplett)

1. Goldhirsch A, Gelber RD, Piccart-Gebhart, MJ et al.; Herceptin Adjuvant (HERA) Trial Study Team. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013;382(9897):1021-8.

Statement HER2 positiv (bei pCR): pN+ Trastuzumab + Pertuzumab (bis 12 Mon. komplett)

1. von Minckwitz G, Procter M, de Azambuja E, et al. APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and

Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017 Jul 13;377(2):122-131.

1. Piccart M , Procter M, Fumagalli D et al. Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer. SABCS 2019; abstr. GS 01-04

Statement HER2 positiv (bei non-pCR) T-DM1 (bis 12 Mon. anti-HER2-Therapie komplett)

1. von Minckwitz G, Huang CS, Mano MS et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019;380(7):617-628

Statement HER2 positiv (bei non-pCR) Neratinib (1 Jahr) nach 1 Jahr Trastuzumab (nur bei HR-positiv)


1. Martin M et al.; ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(12):1688-1700

Statement HER2 positiv (bei non-pCR): Trastuzumab + Pertuzumab (bis 12 Mon. komplett)

1. von Minckwitz G, Procter M, de Azambuja E, et al. APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017 Jul 13;377(2):122-131.
2. Piccart M , Procter M, Fumagalli D et al. Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer. SABCS 2019; abstr. GS 01-04

Statement Tripel negativ (TNBC) (bei non-pCR) Capecitabine (8 Kurse)

1. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. *N Engl J Med*. 2017;376(22):2147-2159.
2. Lluch A, Barrios CH, Torrecillas L, et al. Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). *J Clin Oncol*. 2020;38(3):203–213. doi:10.1200/JCO.19.00904
3. Van Mackelenbergh M, Seiter F, Möbus V et al. Effects of capecitabine as part of neo-/adjuvant chemotherapy. A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients. *SABCS 2019*, abstr. GS1-07



© AGO e. V.
in der DGGG e.V.
sowie
in der DKG e.V.

Guidelines Breast
Version 2020.1

www.ago-online.de

FORSCHEN
LEHREN
HEILEN

Biosimilars

General Considerations

Biosimilars that are used for treatment (i.e. trastuzumab) and supportive care of breast cancer (i.e G-CSF) must be approved by the respective regulatory authorities (EMA, FDA) after passing the stringent development and validation processes required before being used in daily practise.*

* Thill M et al. Einführung und Verwendung von biosimilaren Antikörpern in der Therapie des Mammakarzinoms. Geburtshilfe Frauenheilkd 2018; DOI: 10.1055/s-0043-118761

1. Thill M Schmidt M, Lux,M et al. Einführung und Verwendung von biosimilaren Antikörpern in der Therapie des Mammakarzinoms. Geburtshilfe Frauenheilkd 2018;78(1):41-44
2. Thill M. New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer. Expert Rev Anticancer Ther. 2015;15(3):331-8.
3. Tabernero J, Vyas M, Giuliani R et al. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. ESMO Open. 2017;1(6):e000142.
4. Jacobs I, Ewesuedo R, Lula S et al. Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence. BioDrugs. 2017;31(1):1-36.